Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China (mainland).
Guangdong Provincial Key Laboratory of Organ Donation and Transplant Immunology, Guangzhou, Guangdong, China (mainland).
Med Sci Monit. 2018 Feb 18;24:997-1007. doi: 10.12659/msm.909059.
BACKGROUND The inherent challenges of selecting an acceptable donor for the increasing number and acuity of recipients has forced programs to take increased risks, including accepting donors with a cancer history (DWCH). Outcomes of organ transplantation using organs from DWCH must be clarified. We assessed transplant outcomes of recipients of organs from DWCH. MATERIAL AND METHODS Retrospective analysis of the Scientific Registry of Transplant Recipients data from January 1, 2000 to December 31, 2014 identified 8385 cases of transplants from DWCH. A Cox-proportional hazard regression model and log-rank test were used to compare patient survival and hazard levels of various cancer types. RESULTS DWCH was an independent risk factor of 5-year patient survival (HR=1.089, 95% CI: 1.009-1.176, P=0.03) and graft survival (HR=1.129, 95% CI: 1.056-1.208, P<0.01) in liver and heart transplantation (patient survival: HR=1.112, 95% CI: 1.057-1.170, P<0.01; graft survival: HR=1.244, 95% CI: 1.052-1.472, P=0.01). There was no remarkable difference between the 2 groups in kidney and lung transplantation. Donors with genitourinary and gastrointestinal cancers were associated with inferior outcomes in kidney transplantation. Transplantation from donors with central nervous system cancer resulted in poorer survival in liver transplant recipients. Recipients of organs from donors with hematologic malignancy and otorhinolaryngologic cancer had poorer survival following heart transplantation. CONCLUSIONS Under the current donor selection criteria, recipients of organs from DWCH had inferior outcomes in liver and heart transplantation, whereas organs from DWCH were safely applied in kidney and lung transplantation. Specific cancer types should be cautiously evaluated before performing certain types of organ transplantation.
由于需要不断增加供体数量以满足不断增加的受者数量,且供体的匹配程度也变得更为复杂,这给供体选择带来了固有挑战,这迫使项目承担了更高的风险,包括接受有癌症病史的供体(DWCH)。必须阐明使用 DWCH 供体器官进行器官移植的结果。我们评估了接受 DWCH 供体器官的受者的移植结果。
回顾性分析 2000 年 1 月 1 日至 2014 年 12 月 31 日的 Scientific Registry of Transplant Recipients 数据,确定了 8385 例来自 DWCH 的移植病例。使用 Cox 比例风险回归模型和对数秩检验比较了各种癌症类型的患者生存率和危险水平。
DWCH 是肝移植和心脏移植 5 年患者生存率(HR=1.089,95%CI:1.009-1.176,P=0.03)和移植物生存率(HR=1.129,95%CI:1.056-1.208,P<0.01)的独立危险因素。在肾移植和肺移植中,两组之间没有显著差异。泌尿生殖系统和胃肠道癌症的供体与肾移植的不良结局相关。中枢神经系统癌症供体的移植导致肝移植受者的生存率降低。接受血液系统恶性肿瘤和耳鼻喉癌供体器官的心脏移植受者的生存率较低。
在当前的供体选择标准下,DWCH 供体器官的受者在肝移植和心脏移植中预后较差,而 DWCH 供体器官可安全应用于肾和肺移植。在进行某些类型的器官移植之前,应谨慎评估特定类型的癌症。